Search results for "Phenprocoumon"

showing 8 items of 28 documents

SPECIES-DEPENDENT STEREOSPECIFIC SERUM PROTEIN BINDING OF PHENPROCOUMON

1978

PhenprocoumonStereospecificityBiochemistryChemistrymedicineSerum proteinmedicine.drug
researchProduct

Disposition and Anticoagulant Activity of the Enantiomers of Phenprocoumon in Phenobarbital Pretreated Rats

1978

The purpose of this study was to assess in rats the effect of enzyme induction on the stereoselective disposition and anticoagulant activity of phenprocoumon.

PhenprocoumonbiologyChemistrybiology.proteinmedicineStereoselectivityPhenobarbitalDispositionEnzyme inducerPharmacologyEnantiomerAnticoagulant activitymedicine.drug
researchProduct

Fatal cerebellar haemorrhage due to phenprocoumon poisoning.

1996

A 32-year-old patient died of a cerebellar haemorrhage and the blood coagulation analysis before death suggested defective synthesis of vitamin K-dependent clotting factors due to vitamin K deficiency. The post-mortem toxicological examination of different tissues revealed phenprocoumon poisoning as the cause of death. The differential diagnosis of vitamin K deficiency and the toxicology of hydroxycoumarins are discussed.

VitaminAdultMalemedicine.medical_specialtyBrain DeathPoison controlGastroenterologyPathology and Forensic MedicinePhenprocoumonchemistry.chemical_compoundCerebellar DiseasesInternal medicineVitamin K deficiencyMedicineHumansCause of deathCerebral HemorrhageClotting factorDose-Response Relationship Drugbusiness.industryWarfarinBrainmedicine.diseaseSurgerychemistryPhenprocoumonVitamin K DeficiencyBlood Coagulation TestsDifferential diagnosisDrug Overdosebusinessmedicine.drugInternational journal of legal medicine
researchProduct

Age-dependent differences in the effect of phenprocoumon on the vitamin K1-epoxide cycle in rats

1980

Abstract The anticoagulant activity and the pharmacokinetics of phenprocoumon as well as the effect of phenprocoumon on the vitamin K1-epoxide cycle in younger (12 weeks) and older (36 weeks) male inbred Lewis rats has been examined in a study of the mechanism responsible for the increase in the responsiveness to oral anticoagulant drugs (OAD's) with increasing age. After a single i.v.-dose of phenprocoumon (0†355 mg kg−1 the anticoagulant effect obtained was greater in older than in younger rats. There were no differences between younger and older rats in the rate of elimination, volume of distribution and in the free fraction and free concentration values of phenprocoumon in plasma and li…

VitaminMetabolitePharmaceutical SciencePharmacologyReductasePhenprocoumonchemistry.chemical_compoundPharmacokineticsEthers CyclicmedicineAnimalsPharmacologyVolume of distributionchemistry.chemical_classificationDose-Response Relationship DrugChemistryAge Factors4-HydroxycoumarinsVitamin K 1RatsKineticsEnzymeLiverFree fractionPhenprocoumonEpoxy Compoundsmedicine.drugJournal of Pharmacy and Pharmacology
researchProduct

(3RS,1SR)-3-Bromo-3-(1-phenylpropyl)chroman-2,4-dione

2005

The title compound, C18H15BrO3, was obtained by bromination of phenprocoumone with N-bromo­succin­imide. The X-ray structure confirms an earlier proposal concerning the regioselectivity of the reaction to introduce the Br atom at the 3-position.

chemistry.chemical_compoundchemistryHalogenationRegioselectivityAtom (order theory)General Materials ScienceGeneral ChemistryCondensed Matter PhysicsImideMedicinal chemistryPhenprocoumoneActa Crystallographica Section E Structure Reports Online
researchProduct

Evaluation of oral anticoagulation therapy: Rationale and design of the thrombEVAL study programme

2013

Since decades, oral anticoagulation (OAC) with vitamin K antagonists (VKA) is an established therapy for both prevention and treatment of thromboembolism in daily clinical routine. Increasing life expectancy, demographic changes, and novel oral anticoagulants have led to an increasing complexity of medical therapy. However, data on quality and management of VKA therapy with phenprocoumon in current medical care are limited. Our aim is to investigate the quality of OAC with VKA in current health care and to evaluate the potential for improvements.The investigator-initiated thrombEVAL study programme comprises two cohorts of patients treated with vitamin K antagonists for oral anticoagulation…

medicine.medical_specialtyVitamin KEpidemiologymedicine.drug_classAdministration OralVitamin kPhenprocoumonThromboembolismmedicineHumansProspective StudiesQuality of careIntensive care medicineOral anticoagulationQuality of Health Carebusiness.industryAnticoagulantsVitamin K antagonistClinical routineTelemedicineResearch DesignIschemic strokePhenprocoumonCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Journal of Preventive Cardiology
researchProduct

Drug-induced hepatitis: a rare complication of oral anticoagulants.

1994

Hepatotoxicity is a rare complication of coumarin anticoagulants. We present the case of a 56-year-old woman who developed a viral-hepatitis-like picture 8 months after mitral valve replacement and oral anticoagulation. Phenprocoumon-induced hepatitis was diagnosed after positive reexposure and improvement following withdrawal of the drug. There appeared to be cross-reactivity to warfarin since this drug led to a similar increase in alkaline phosphatase and gamma-glutamyl transferase after a few days of administration. Liver biopsy showed an acute viral-hepatitis-like picture. Anticoagulation was changed to a subcutaneous low molecular weight heparin and low-dose aspirin. Because of the wid…

medicine.medical_specialtymedicine.drug_classBiopsyLow molecular weight heparinAdministration OralGastroenterologyInternal medicinemedicineHumansHepatitisAspirinHepatologymedicine.diagnostic_testbusiness.industryIncidenceAnticoagulantWarfaringamma-GlutamyltransferaseMiddle Agedmedicine.diseaseAlkaline PhosphataseSurgeryLiverLiver biopsyPhenprocoumonFemaleWarfarinChemical and Drug Induced Liver InjurybusinessViral hepatitisComplicationmedicine.drugJournal of hepatology
researchProduct

Interaction of allopurinol with phenprocoumon in man.

1977

Conditions in two patients on long-term phenprocoumon (Marcumar®) treatment are reported who had signs of phenprocoumon overdosage when given simultaneously allopurinol. The determination of phenprocoumon plasma concentrations in one patient showed that phenprocoumon accumulates for several weeks during treatment with allopurinol. Signs of phenprocoumon overdosage thus can appear long time after starting allopurinol treatment.

musculoskeletal diseasesAdultMalecongenital hereditary and neonatal diseases and abnormalitiesAllopurinolMyocardial InfarctionAllopurinolPharmacologyPhenprocoumonDrug DiscoveryMedicineHumansDrug InteractionsBlood CoagulationGenetics (clinical)integumentary systembusiness.industrynutritional and metabolic diseasesGeneral Medicine4-HydroxycoumarinsDrug interactionMiddle AgedPlasma concentrationPhenprocoumonMolecular MedicineBlood Coagulation TestsbusinessMathematicsmedicine.drugKlinische Wochenschrift
researchProduct